Why wasn’t Lucy Letby’s evidence heard after the trial
The Lucy Letby case continues to draw attention because several lines of medical and statistical analysis never reached the jury or the appeals court in full. Critics now argue that the original trial rested on selective readings of clinical signs and incomplete data sets, while fresh expert reviews raise doubts about whether those interpretations were complete or even accurate. The result is an ongoing debate about what counts as decisive proof in complex neonatal cases and why later submissions have struggled to reopen the record.
Shoo Lee panel review
Fourteen neonatologists and paediatric specialists examined the same medical records presented at trial. They concluded that skin discolouration and other signs cited as evidence of air embolism did not match established patterns and pointed instead to thrombosis or infection.
The panel also revisited the 1989 paper co-authored by chair Dr. Shoo Lee, which the prosecution had used to support claims of injected air. Lee stated the source material had been applied beyond its original scope and did not substantiate deliberate harm in any of the seventeen cases.
The full report, delivered to the Criminal Cases Review Commission in early 2025, found no clinical indication of malfeasance across the babies involved. Its conclusions directly challenge the medical pillar of the prosecution case that the jury never had an opportunity to weigh against opposing expert opinion.
Insulin test disputes
Two babies were central to allegations of insulin poisoning, based on immunoassay results from the Royal Liverpool Hospital laboratory. Post-trial toxicologists and endocrinologists argue that the Roche method used is flagged internally as unsuitable for detecting exogenous insulin in neonates and can generate elevated readings without external confirmation.
An 86-page dossier submitted in April 2025 notes that no evidence of missing insulin vials was recorded on the ward at the time. The experts further contend that C-peptide ratios presented at trial may reflect laboratory artefact rather than synthetic administration.
These forensic concerns were not tested by a defence witness during the original proceedings, leaving the insulin evidence unchallenged in front of the jury and later appeals.
Statistical framing issues
Prosecutors presented a table showing Lucy Letby on duty during each charged incident. Statisticians later pointed out that the table excluded other deaths and collapses on the unit during the same period, creating an incomplete picture of staffing patterns.
Professor Jane Hutton and colleagues at the Royal Statistical Society noted that selective subsets can distort perceived associations, a problem previously highlighted in the Sally Clark wrongful conviction. Dewi Evans later referenced a “30 times more likely” figure outside court that was never introduced as evidence.
The Royal Statistical Society issued guidance in 2024 on the risks of such presentations in medical misconduct investigations, underscoring that full data sets were not available for the jury to assess.
Defence expert absence
No neonatologist was called by the defence to counter the prosecution’s medical witnesses despite the volume of clinical detail introduced over more than one hundred trial days. Observers note that this left interpretations of x-rays, blood gases, and timing unchallenged in real time.
Critics argue the absence reflected both resource limits and procedural decisions rather than a lack of available specialists. The result was a one-sided expert landscape that later panels have sought to balance.
Because the defence did not present alternative medical testimony, subsequent attempts to introduce such material on appeal faced strict “fresh evidence” thresholds that the Court of Appeal ruled were not met.
Appeal and CCRC process
The Court of Appeal rejected applications that included the Shoo Lee panel findings, stating the material either could have been obtained earlier or did not meet the legal standard for reopening the case. Two separate refusals occurred by October 2024.
The Criminal Cases Review Commission is now assessing multiple submissions, including the insulin report and statistical critiques, with a decision timeline extending into 2026. The Commission’s role is to determine whether new evidence creates a real possibility that convictions would not be upheld.
Meanwhile the Crown Prosecution Service announced in January 2026 that it would not pursue charges related to additional babies, citing insufficient evidence beyond the original convictions.
Thirlwall Inquiry scope
The public inquiry into events at Countess of Chester Hospital operated on the premise that the convictions were sound. Its terms of reference focused on institutional and cultural factors rather than re-examination of the medical evidence itself.
Some MPs, including Jeremy Hunt and David Davis, have questioned whether the inquiry’s conclusions can be considered complete without addressing the contested clinical findings now before the CCRC.
The inquiry report is expected later in 2026, but its framing means any recommendations on systemic reform will sit alongside unresolved questions about the original medical interpretations.
International comparisons
Similar concerns over expert testimony and statistical presentation have surfaced in U.S. cases involving healthcare workers accused of patient harm. Courts there have increasingly required independent review panels before allowing complex medical theories to reach juries.
The Lucy Letby proceedings echo earlier UK miscarriages such as Sally Clark, where flawed statistical framing contributed to wrongful convictions later overturned. Those precedents now inform calls for procedural safeguards in neonatal death investigations.
Advocates for review argue that the absence of competing expert analysis at trial placed an unusually heavy burden on the jury to evaluate technical disputes without the benefit of balanced testimony.
Media and public response
Coverage since the February 2025 panel press conference has shifted from acceptance of the verdicts toward examination of the medical and statistical gaps. Broadcasters and parliamentary debate have referenced the Lee findings and insulin dossier without asserting innocence or guilt.
Online discussion has centered on the difference between presence data and causation, with some commentators drawing parallels to true-crime documentaries that revisit contested forensic evidence years later.
Public interest remains high because the case sits at the intersection of healthcare accountability and standards of proof, prompting renewed attention to how juries receive complex scientific material.
Next procedural steps
The CCRC continues to collect and evaluate submissions, including additional expert statements on air embolism diagnostics and laboratory protocols. Any decision to refer the case back to the Court of Appeal would require demonstration that the new material creates a realistic chance of quashing the convictions.
Campaigners are also pressing for disclosure of internal hospital records and laboratory correspondence that were not produced at trial. These documents could clarify whether the limitations of the Roche insulin assay were known to investigators at the time.
Until the Commission completes its review, the central question remains whether the medical and statistical analyses now in circulation would have altered the jury’s assessment had they been presented and tested during the original proceedings.
Forward implications
The Lucy Letby case illustrates how tightly courts control the admission of post-trial expert analysis and how difficult it can be to reopen convictions once appeals are exhausted. Whether the CCRC ultimately refers the matter will depend on the strength of the new medical and statistical dossiers rather than public debate alone.
